Long-term treatment with citalopram in patients with highly recurrent forms of unipolar depression

The authors evaluated the efficacy and safety of citalopram in a 28-month study in 48 inpatients with highly recurrent forms of unipolar depression. The patients, who each had at least one depressive episode during the 18 months preceding the index episode, were openly treated with citalopram, 40 mg...

Full description

Saved in:
Bibliographic Details
Published in:Psychiatry research 2001-12, Vol.105 (1), p.129-133
Main Authors: Franchini, Linda, Spagnolo, Chiara, Rampoldi, Raffaella, Zanardi, Raffaella, Smeraldi, Enrico
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Citalopram - administration & dosage
Citalopram - adverse effects
Depressive Disorder, Major - diagnosis
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - psychology
Female
Humans
Long-Term Care
Long-term therapy
Male
Medical sciences
Middle Aged
Neuropharmacology
Personality Inventory
Pharmacology. Drug treatments
Prevention
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Recurrence
Recurrent major depression
Relapse
Selective serotonin reuptake inhibitors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The authors evaluated the efficacy and safety of citalopram in a 28-month study in 48 inpatients with highly recurrent forms of unipolar depression. The patients, who each had at least one depressive episode during the 18 months preceding the index episode, were openly treated with citalopram, 40 mg/day. Thirty-six of the patients had a stable response to citalopram and continued treatment as outpatients for 4 months. No relapses were observed. At the time of recovery, 32/36 subjects received maintenance treatment with citalopram (40 mg) for an additional 24 months. At the end of the study, 11/32 patients experienced a single new recurrence.
ISSN:0165-1781
1872-7123
DOI:10.1016/S0165-1781(01)00336-5